Alterity Therapeutics Limited (ATHE) FinancialsATHEAlterity Therapeutics Limited

Alterity Therapeutics Limited (ATHE) generates its revenue primarily from Reaserch and development in the field of Paekinsonaian movement disorders, which accounts for 100.0% of total sales, equivalent to $10.89K. Understanding this concentration is critical for investors evaluating how ATHE navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Alterity Therapeutics Limited maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1354.69%, while the net margin is -1056.98%. These profitability ratios, combined with a Return on Equity (ROE) of -45.94%, provide a clear picture of how effectively ATHE converts its operational activities into shareholder value.

In the context of the broader market, ATHE competes directly with industry leaders such as GNLX and BMEA. With a market capitalization of $86.64M, it holds a significant position in the sector. When comparing efficiency, ATHE's gross margin of 100.00% stands against GNLX's N/A and BMEA's N/A. Such benchmarking helps identify whether Alterity Therapeutics Limited is trading at a premium or discount relative to its financial performance.

The company's financials show a forward P/E of 0, indicating no earnings expected in the near term, and a price-to-sales ratio of 12.45, suggesting the stock may be overvalued based on sales.